Predictive Oncology Inc. (POAI) |
|
3.2 0.15 (4.92%)
|
09-29 15:59 |
|
Open: |
3.16 |
Pre. Close: |
3.05 |
|
High:
|
3.2992 |
Low:
|
3.1587 |
|
Volume:
|
9,031 |
Market Cap:
|
13(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:29:44 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.69 One year: 5.48 |
| Support: |
Support1: 2.92 Support2: 2.42 |
| Resistance: |
Resistance1: 4.02 Resistance2: 4.69 |
| Pivot: |
3.23  |
| Moving Average: |
MA(5): 3.16 MA(20): 3.45
MA(100): 4.24 MA(250): 5.86 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 23.9 %D(3): 21 |
| RSI: |
RSI(14): 37.6 |
| 52-week: |
High: 13.88 Low: 2.47 |
| Average Vol(K): |
3-Month: 52 (K) 10-Days: 17 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ POAI ] has closed above bottom band by 45.5%. Bollinger Bands are 52.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.3 - 3.32 |
3.32 - 3.33 |
|
Low:
|
3.12 - 3.14 |
3.14 - 3.15 |
|
Close:
|
3.17 - 3.2 |
3.2 - 3.22 |
|
Company Description |
|
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. |
Headline News |
Tue, 29 Aug 2023
Is Predictive Oncology Inc (POAI) Stock a Smart Investment Tuesday? - InvestorsObserver
Sat, 12 Aug 2023
Predictive Oncology Inc. (NASDAQ:POAI) Q2 2023 Earnings Call Transcript - Yahoo Finance
Thu, 10 Aug 2023
Predictive Oncology dramatically narrows its quarterly loss in latest ... - Proactive Investors USA
Thu, 10 Aug 2023
Predictive Oncology Reports Second Quarter 2023 Financial ... - GlobeNewswire
Tue, 18 Jul 2023
Predictive Oncology moves company headquarters to Pittsburgh - Proactive Investors USA
Tue, 27 Jun 2023
Predictive Oncology Inc (POAI) Up 6.19% in Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Instruments & Supplies |
| Shares Out. |
0 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
3.59e+006 (%) |
|
% Held by Institutions
|
3.2 (%) |
|
Shares Short
|
302 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.474e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
21.1 |
|
Return on Equity (ttm)
|
-34.5 |
|
Qtrly Rev. Growth
|
1.55e+006 |
|
Gross Profit (p.s.)
|
20.58 |
|
Sales Per Share
|
-51.68 |
|
EBITDA (p.s.)
|
645161 |
|
Qtrly Earnings Growth
|
-4.9 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-13 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.07 |
|
Price to Cash Flow
|
1.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
264350 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
